Lifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Aron R. English Sells 45,698 Shares

Lifecore Biomedical, Inc. (NASDAQ:LFCR) major shareholder Aron R. English sold 45,698 shares of Lifecore Biomedical stock in a transaction on Monday, May 12th. The stock was sold at an average price of $7.03, for a total transaction of $321,256.94. Following the sale, the insider now directly owns 1,662,574 shares in the company, valued at approximately $11,687,895.22. This trade represents a 2.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Lifecore Biomedical Trading Down 4.0%

Shares of LFCR opened at $6.67 on Thursday. Lifecore Biomedical, Inc. has a 52-week low of $3.68 and a 52-week high of $7.99. The company has a quick ratio of 1.21, a current ratio of 2.32 and a debt-to-equity ratio of 9.21. The firm’s fifty day moving average is $6.46 and its two-hundred day moving average is $6.52. The stock has a market cap of $246.96 million, a PE ratio of -11.91 and a beta of 0.65.

Lifecore Biomedical (NASDAQ:LFCR) last announced its earnings results on Thursday, April 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. The business had revenue of $35.15 million for the quarter, compared to analyst estimates of $33.23 million. Research analysts forecast that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lifecore Biomedical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Summit Securities Group LLC acquired a new stake in Lifecore Biomedical during the 1st quarter worth $26,000. Boston Partners acquired a new stake in Lifecore Biomedical during the 1st quarter worth $241,000. Nuveen LLC purchased a new position in shares of Lifecore Biomedical during the 1st quarter worth $203,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Lifecore Biomedical by 6.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 79,495 shares of the company’s stock worth $560,000 after acquiring an additional 5,068 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Lifecore Biomedical during the 1st quarter worth $145,000. Institutional investors and hedge funds own 83.36% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.